Reuters logo
BRIEF-Recro Pharma amends Alkermers Pharma development milestone payment terms
December 8, 2016 / 12:39 PM / 10 months ago

BRIEF-Recro Pharma amends Alkermers Pharma development milestone payment terms

Dec 8 (Reuters) - Recro Pharma Inc

* Recro pharma inc - if company elects deferral option, $10 million milestone payment will be increased to $15 million

* Recro pharma inc - entered into a first amendment to purchase and sale agreement, dated as of march 7, 2015 - sec filing

* Recro pharma - amendment revises payment terms of development milestone earn-out consideration due from co to alkermes pharma

* Recro pharma inc - co may elect, at its option, to defer $10 million milestone payment otherwise due upon filing of new drug application as per amendment Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below